Because DPP-4 inhibitors are less effective at lowering blood glucose than other diabetes medications, we were concerned that patients prescribed DPP-4 inhibitors might have had less severe diabetes., To address this potential bias, we examined whether COVID-19 severity differed based on insulin use. The gene discussed is DPP4; the disease is diabetes mellitus.